Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 29, 2020 09:45 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Provides Fiscal 2020 Year-End Business Update

Identifies “Triglyceride Normalization” phenomenon prior to patient randomization and treatment as likely contributor to unusually high placebo effect in TRILOGY 1 Acasti management to host...
June 19, 2020 08:00 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package

LAVAL, Québec, June 19, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development...
April 30, 2020 08:30 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA

FDA response expected on or before June 30, 2020 Acasti also received notice of issuance of a Composition of Matter Patent in Hong Kong LAVAL, Quebec, April 30, 2020 (GLOBE NEWSWIRE) -- Acasti...
April 20, 2020 08:30 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada

LAVAL, Québec, April 20, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development...
April 01, 2020 08:30 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June

LAVAL, Québec, April 01, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development...
March 11, 2020 08:00 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico

Patent upheld in Japan following opposition filings and subsequently allowed Completes TRILOGY 1 audits and accelerates plans to submit FDA meeting request by the end of March LAVAL, Québec,...
February 28, 2020 17:00 ET | Source: Acasti Pharma, Inc.

Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements

LAVAL, Québec, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development...
February 14, 2020 08:00 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020

LAVAL, Québec, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development...
February 13, 2020 09:00 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call

LAVAL, Quebec, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and...
February 10, 2020 07:00 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre

Investigation underway into unexpected and inconsistent findings that may have negatively impacted results reported in TRILOGY 1 Announces plans to seek FDA guidance prior to unblinding TRILOGY 2...